Evidence map›Paper›PMID 31182324›Full record

ArticleVaccine2019

Regional variations in human papillomavirus prevalence across time in NHANES (2003-2014).

Jacqueline M Hirth, Yong-Fang Kuo, Jonathan M Starkey, Richard E Rupp, Tabassum H Laz, Mahbubur Rahman, Abbey B Berenson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jacqueline M HirthCenter for Interdisciplinary Research in Women's Health, Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, TX, United States. Electronic address: jmhirth@utmb.edu.
Yong-Fang KuoDepartment of Biostatistics and Epidemiology, University of Texas Medical Branch, Galveston, TX, United States.
Jonathan M StarkeyInstitute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, United States.
Richard E RuppDepartment of Pediatrics, University of Texas Medical Branch, Galveston, TX, United States.
Tabassum H LazDepartment of Radiology, St. Luke's International Hospital, Tokyo, Japan.
Mahbubur RahmanDivision of Epidemiology, Graduate School of Public Health, St. Luke's International University, Tokyo, Japan.
Abbey B BerensonCenter for Interdisciplinary Research in Women's Health, Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, TX, United States.

Funding

UTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0M
UTMB WOMEN'S HEALTH RESEARCH SCHOLARS PROGRAMK12HD052023 · NICHD · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI BERENSON, ABBEY B · 2005 to 2023
$8.1M
NCATS NIH HHS UL1 TR001439NCI NIH HHS L30 CA179596NICHD NIH HHS K12 HD052023
6 · The paper itself

Abstract

introductionThe consequences of low human papillomavirus (HPV) vaccination in Census regions with higher incidence of cervical cancer may contribute to continued disparities. Our purpose was to evaluate regional variations in HPV prevalence across time.

methodsRepeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), 2003-2014 were examined. Participants included females 14 to 34 years old who provided adequate vaginal samples for HPV DNA typing (N = 6387). Region of residence and HPV vaccination status associations with HPV prevalence were examined using chi-square and multivariable logistic regression. HPV types were grouped according to vaccine-type HPV (types 6, 11, 16, 18) and risk (high or low-risk). Time and vaccination status were included in subsequent models for post-licensure survey cycles (2007-2014) to assess their effects on observed associations.

resultsNo decreases in vaccine-type HPV prevalence were found between the prevaccine cycles (2003-2006) and early post-licensure cycles (2007-2010, p > 0.05). Vaccine-type HPV prevalence decreased in late post-licensure years (2011-2014) compared to prevaccine years (2003-2006, p = 0.001). The highest prevalence of vaccine-type HPV occurred in the South (8.6%) and Midwest (8.6%), followed by the West (4.8%), and the Northeast (3.5%) in late post-licensure years. Lower odds of vaccine-type HPV across time in post-licensure survey cycles were found to be attributable to time, and more strongly to HPV vaccination.

conclusionsThere were regional variations in vaccine-type HPV prevalence between prevaccine and post-licensure years. These decreases appeared to be at least partially attributable to HPV vaccination. Programs are needed to address geographical disparities in HPV vaccination.

Indexed as

AdolescentAdultCross-Sectional StudiesFemaleHumansLogistic ModelsPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesPrevalenceUterine Cervical NeoplasmsVaccinationVaginaYoung AdultPapillomavirus VaccinesCancer preventionGeographic disparitiesHPV prevalenceHPV vaccinationVaginal HPV

Identifiers

PMID31182324
PMCPMC6599727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.